Share this article on:

Vaccine Failures in Patients Properly Vaccinated with 13-Valent Pneumococcal Conjugate Vaccine in Catalonia, a Region with Low Vaccination Coverage

Moraga-Llop, Fernando MD; Garcia-Garcia, Juan-Jose PhD; Díaz-Conradi, Alvaro PhD; Ciruela, Pilar PhD; Martínez-Osorio, Johanna MD; González-Peris, Sebastià MD; Hernández, Sergi MSc; de Sevilla, Mariona Fernández PhD; Uriona, Sonia MD; Izquierdo, Conchita PhD; Selva, Laura PhD; Campins, Magda PhD; Codina, Gemma PhD; Batalla, Joan PhD; Esteva, Cristina PhD; Domínguez, Àngela PhD; Muñoz-Almagro, Carmen PhD

The Pediatric Infectious Disease Journal: April 2016 - Volume 35 - Issue 4 - p 460–463
doi: 10.1097/INF.0000000000001041
Brief Reports

Vaccine failures occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in 3 pediatric hospitals in Barcelona (2012–2013) are described. PCV13 vaccine failure was defined as the occurrence of an invasive pneumococcal infection in children properly vaccinated by PCV13. Among 84 patients with invasive pneumococcal infection, 32 had received at least one dose of PCV13. Seventeen of them had invasive pneumococcal infection produced by a PCV13 serotype. Among those, 9 patients were considered to have a PCV13 vaccine failure. Serotype 3 was isolated in 6 patients, serotype 19A in 2 and serotype 6B in 1.

From the *Pediatrics, Hospital Vall d’Hebron, Barcelona, Spain; Pediatrics, Hospital Sant Joan de Déu, Barcelona, Spain; Pediatrics, Hospital de Nens, Barcelona, Spain; §Departament de Salut, Agència de Salut Pública de Catalunya, Barcelona, Spain; Microbiology, Hospital Vall d’Hebron, Barcelona, Spain; Preventive Medicine, Hospital Vall d’Hebron, Barcelona, Spain; **CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; ††Molecular Microbiology, Hospital Sant Joan de Déu, Barcelona, Spain; and ‡‡ Departament de Salut Pública, Universitat de Barcelona, Barcelona, Spain.

Accepted for publication September 10, 2015.

Supported by the PI11/02081 and PI11/02345 projects, integrated in the Plan Nacional de I+D+I and funded by the ISCIII - Subdirección General de Evaluación y Fomento de la Investigación Sanitaria - and by the Fondo Europeo de Desarrollo Regional (FEDER).

F.M.-L., J.-J.G.-G. and M.C. have received honoraria for conferences by Pfizer Inc. All the other authors have no conflicts of interest.

Address for correspondence: Juan-Jose Garcia-Garcia, PhD, Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Passeig Sant Joan de Déu 2, 08950 Esplugues de Llobregat, Barcelona, Spain. E-mail:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.